Abstrak
anion channels (VDACs) are mainly found in the outer membrane of mitochondria. 4 These channels also known as porins are responsible for the flux of ions and metabolites including ATP from and to mitochondria in the cell. [5] [6] [7] There are three different VDAC genes encoding distinct isoforms in mammals, i.e. VDAC1, VDAC2 and VDAC3. Each of these proteins is highly conserved in human, rat and mouse. VDAC proteins are found also in cattle and in the tail of human sperm. [8] [9] [10] A "VDAC3-deficient mouse" study revealed low sperm motility of homozygote mutant mice. 11 Our
The fast population growth in many countries, such as Indonesia, has been a major problem; therefore, the family planning program needs to be implemented widely and effectively. Until recently, male contraception was always associated with the problems of low efficiency, irreversibility and unwanted side effects. Development of tools or materials for male contraception is still underway, one of them is the immune-contraception method. 1, 2 One of the target proteins that can affect sperm function is the specific ion channel protein on the sperm. 3 Voltage dependent study showed various mutations in exons 5, 6, 7 and 8 of VDAC3 gene which occurred in low motile sperm from asthenozoospermic patients. 12, 13 In our previous studies with a porin 2 (VDAC2) polyclonal antibody decrease of bovine sperm motility was statistically not significant, whereas a VDAC3 polyclonal antibody decreased human sperm motility significantly. 14, 15 Providing monoclonal antibodies against spermspecific proteins in order to diminish sperm function is prospective in the development of male contraceptive strategies. 1 The aim of this study was to design human sperm-specific VDAC3 cDNA and to construct a recombinant vector of its gene.
METHODS

Primer design
We refer to gene bank Acc No. NM_005662 (http://www. ncbi.nlm.nih.gov/pubmed/) with target sequences of exons 5, 6, 7 and 8 of the VDAC3 gene. The primer design for this study is based on previous studies in an attempt to cover the expression of VDAC3 gene starting from exon 5 through exon 8, i.e. 5' TTGGCTGAAGGGTTGAAACT 3' and 5' GAGAAGTTCTACAATCCAGC 3'. These primer pairs were used to amplify VDAC3 cDNA from human sperm cells, which yielded an amplicon size of 428 bp as target sequence for the construction of a recombinant vector.
Human sperm collection
Human normozoospermic sperm was isolated by Percoll-density gradient centrifugation (45% and 90%) using Percoll solution (Pharmacia, Uppsala Sweden) in Cramer medium. Spermatozoa were collected from the bottom layer (density of 90%). The sperm pellet was washed and stored in -20 o C.
Sperm RNA isolation and cDNA VDAC3 production
Total sperm mRNA was extracted by using TRIzol reagent (Invitrogen, Carlsbad USA) and DNA contamination was digested by DNase. Synthesis of cDNA (reverse transcription) was catalyzed by Superscript III RT (Invitrogen, Carlsbad USA). Amplification of VDAC3 cDNA target sequence used PCR technique (Kapa Biosystem, Boston, USA). The PCR system was performed for 35 cycles at 94 (Figure 1 ), the forward primer was added by CACC ATG overhang sequence. The integrity and yield of the product was confirmed by agarose gel electrophoresis using a 100 bp DNA ladder as marker.
Construction of a VDAC3 gene recombinant vector
Insertion of VDAC3 gene target to pET 101/D-TOPO vector using the TOPO directional cloning system and subsequent transformation to E. coli TOP 10 competent cells using TOPO directional cloning as well as transformation reactions were performed according to the Invitrogen protocol (Invitrogen, Carlsbad USA). Positive transformed E. coli was selected on Luria Bertani (LB) medium, and was subsequently analyzed by isolating the recombinant plasmid with the alkaline lyses method by GeneJet Plasmid Purification Kit (Fermentas, Vilnius Lithuania). The insertion of the VDAC3 target sequence was confirmed by restriction enzyme using XbaI as well as by PCR colony method.
RESULTS
The inserted VDAC3 fragment gene in the size of 435 bp -as total length of exons 5 -8 (428 bp) and CACCATG overhang -can be observed on agarose gel electrophoresis of the reverse transcription-PCR product ( Figure 2 ). BLAST analysis showed that the target sequence is a 94% match to human VDAC3 gene Figure 5 ). Sequencing of the PCR colony product was also 94% match to human VDAC3 sequence.
DISCUSSION
In this study, we successfully established a recombinant vector for human sperm VDAC3 gene. The inserted VDAC3 gene was a 94% match to human VDAC3 gene in the databank leading to change 9 amino acids of the VDAC3 polypeptide sequence. The sequence comparison between published hVDAC3 fragment gene and sperm-obtained VDAC3 fragment gene is shown in figure 6 . alternative splicing of a 3-base exon. 17 VDAC3 has 65-70% amino acid similarity to the other two VDAC isoforms. Unlike VDAC1 and VDAC2, VDAC3 is able to only partially complement a temperaturesensitive YVDAC-deficient yeast strain when grown on glycerol-based media, suggesting that this isoform may have distinct physiological functions. 17, 18 The functions of the VDAC3 isoform were demonstrated by a study with mice lacking VDAC3, which showed that male mice were infertile. Although they had normal sperm numbers, spermatozoa exhibited markedly reduced motility. Structural defects were found in two-thirds of epididymal axonemes.
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Three VDAC isoforms are expressed in a wide variety of tissues and cells of mammals including humans. Among the cells in the testis, VDAC1 is mainly located in Sertoli cells, VDAC2 in late spermatocytes and spermatids, and VDAC3 in all cell types of testis, especially in Leydig cells. 9, 19, 20 It has been reported that high amounts of VDAC2 and VDAC3 protein was found in bovine sperm flagella, especially in a subcellular component named outer dense fibres (ODF). Anti-VDAC antibodies against VDAC isoforms functionally lead to a loss of the acrosomal cap, surface alterations of the sperm head, coiled sperm tails and sperm cell volume disturbances. 9, 21 In our preliminary study anti-VDAC2 antibody decreased bovine sperm motility, but these results were statistically not significant.
14
Our subsequent evaluation of anti-VDAC3 antibody demonstrated a significant decrease of human spermatozoa motility. 15 Insertion of the sperm-specific VDAC3 gene to our recombinant vector could be proved by XbaI enzyme cutting in eight colonies of bacteria culture, while only five out of eight colonies showed presence of inserted gene by means of PCR colony method. It may be caused by failure of gene amplification in three colonies.
Based on studies in mammals and humans, we suppose that VDAC protein, especially the VDAC3 isoform perform important functions in sperm normal structure and motility. Generating an antibody towards the VDAC3 isoform that can interfere with these functions might be the first step to develop a male contraception vaccine. Development of a human immunocontraceptive vaccine based on a sperm-specific antigen is a rational concept, because it has long been known that sperm are highly immunogenic in both females and males. Many sperm protein antigens have been investigated as the basis for fertility-regulating vaccines.
1,2 Our spermspecific VDAC3 recombinant vector will further be used to produce purified VDAC3 protein for generating antibodies. In the future, these antibodies might be applied as a passive vaccine that could decrease human sperm motility.
In conclusion, this study has established the construction of a VDAC3 gene recombinant vector generated specifically from human sperm transcript. This vector will be used to produce recombinant VDAC3 protein. This protein will be applied and investigated to generate the antibody for a male contraception vaccine.
